465 CAR-Engineered Extracellular Vesicles From Human Stem Cell-Derived Neutrophils for Glioblastoma Therapy

View at publisher Summarise with VIRAT
Authors: Loizos Michaelides, Colin Esmonde, Sun Li, Yun Chang, Changchun Zeng, Alfredo Quiñones-Hinojosa, Xiaoping Bao, Yan Li
Cited by: 0

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

INTRODUCTION: GBM is a lethal brain tumor with limited therapeutic options, hindered by the blood-brain barrier (BBB). Immune therapies employing chimeric antigen receptor (CAR)-engineered cells show promise but face limitations including immune suppression and off-target effects. Extracellular vesicles (EVs), derived from CAR-engineered neutrophils, may circumvent these issues while retaining targeted tumor cytotoxicity. METHODS: hPSCs were genetically engineered to express CLTX-CAR and differentiated into neutrophils. EVs were isolated at distinct differentiation stages (day 12 hematopoietic progenitors and day 21 neutrophils) via ultracentrifugation, characterized by nanoparticle tracking analysis, transmission electron microscopy, and western blot. Proteomic analysis and miRNA sequencing were conducted on EVs. Uptake and cytotoxicity of EVs were tested in vitro using GBM cell lines (U87MG, LN229) in 2D, apoptosis pathways were analyzed by RT-qPCR and results validated in 3D spheroid models. RESULTS: EV characterization confirmed typical exosomal properties with particle sizes of 150-300 nm and positive exosomal markers. Proteomic and miRNA analysis revealed enriched cargos that could potentially suppress cancer progression through miRNA-mediated regulation of critical genes like PTEN, MYC, and BCL2. CLTX-CAR neutrophil-derived EVs demonstrated effective BBB penetration and targeted GBM cell uptake, significantly reducing cell viability in a dose-dependent manner across both 2D. RT-qPCR analysis showed upregulated pro-apoptotic markers and tumor-suppressive genes (PTEN, p53). Findings were consistent in 3D spheroid models. CONCLUSIONS: CLTX-CAR hPSC-derived neutrophil EVs effectively target GBM cells, bypassing the BBB and inducing potent tumor cytotoxicity via apoptotic and tumor-suppressive cargo. These findings highlight CAR EVs as a novel, safer therapeutic alternative with significant translational potential for GBM treatment.

Fields of Study & Subjects

Extracellular vesicles in disease Nanoparticle-Based Drug Delivery Glioma Diagnosis and Treatment

Publication details

Journal / source
Neurosurgery
Volume
72
Issue
Supplement_1
Pages
136–136
Publication date
26 March 2026
Language
EN